The demand for GLP-1 medications is rapidly increasing, with the market expected to reach $13.6 billion globally by 2028 (source: Research and Markets). Bask Health is well-positioned to meet this demand with its patient-first approach, offering software that supports virtual consultations, medication delivery, and connections to a network of pharmacies and doctors. Driven by technological advancements and changing patient expectations, the telehealth revolution is reshaping healthcare. A recent CMS report shows telehealth services accounted for 32% of outpatient visits in 2023, indicating a permanent shift in healthcare access. Meanwhile, GLP-1 medications, once niche, have gained widespread attention for weight management and metabolic health.

Bask Health’s platform connects patients with licensed providers specializing in GLP-1 medications like semaglutide and liraglutide, allowing patients to manage their health from home. By using secure technology and offering evidence-based treatments, Bask not only improves access but also provides personalized support for lasting health results.

"Telehealth isn't just a trend—it's the future of healthcare," said Zachary Dorf, CEO and Co-Founder of Bask Health. "We’re proud to lead this movement, offering safe, effective software solutions for doctors and entrepreneurs to improve national wellness. As GLP-1 medications change patient outcomes, our mission is to make these treatments accessible to all."

With telehealth adoption in the U.S. surging by over 60% since 2020 (source: McKinsey & Company) and the industry projected to grow into a $225 billion market by 2030 (source: Global Market Insights), Bask Health is redefining the healthcare experience for millions.

Click here to read the original news story.